• Explore /
  • Poster
  • / Coastal: A phase 3 study of the PI3Kδ inhibitor zandelisib with rituximab (R) versus immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL).

Coastal: A phase 3 study of the PI3Kδ inhibitor zandelisib with rituximab (R) versus immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL).

Abstract Video & Slides Poster

Authors

Wojciech Jurczak

Wojciech Jurczak

National Research Institute of Oncology, Kraków, Poland

Wojciech Jurczak , Pier Luigi Zinzani , David Cunningham , Sharon Yavrom , Wenying Huang , Igor Gorbatchevsky , Vincent Ribrag

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT04745832

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS7573)

DOI

10.1200/JCO.2021.39.15_suppl.TPS7573

Abstract #

TPS7573

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Robert W. Chen

First Author: Nathan Hale Fowler

First Author: Nathan Hale Fowler

First Author: Ruemu Ejedafeta Birhiray